Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
NU E Power Corp. Announces Closing of Non-Brokered Private Placement for $1.7 Million. (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Innate Pharma SA IPHA

Healthcare Biotechnology
Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company’s products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome... see more

Current News (NDAQ:IPHA)

Number of Shares and Voting Rights of Innate Pharma as of December 18, 2025

Business Wire December 22, 2025

Innate Pharma Releases Its 2026 Financial Calendar

Business Wire December 11, 2025

Number of Shares and Voting Rights of Innate Pharma as of November 27, 2025

Business Wire November 28, 2025

Innate Pharma to Present at Jefferies Global Healthcare Conference

Business Wire November 17, 2025

Innate Pharma Reports Third Quarter 2025 Business Update and Financial Results

Business Wire November 13, 2025

Innate Pharma Announces FDA Clearance to Proceed With TELLOMAK 3, a Confirmatory Phase 3 Trial of Lacutamab in CTCL

Business Wire November 10, 2025

Innate Pharma Announces Conference Call and Webcast for Third Quarter 2025 Results and Business Updates

Business Wire November 5, 2025

Innate Pharma to Host Analyst and Investor Event on Lacutamab on October 28, 2025

Business Wire October 14, 2025

Innate Pharma Reports First Half 2025 Business Update and Financial Results

Business Wire September 17, 2025
View More News ››

Opinion & Analysis (NDAQ:IPHA)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:IPHA)

Buy buddy buy.

This stock is signalling a big uptrend for shareholders today.
coolfooldumbguy - February 18, 2025
View more Bullboard ››

Playboy Inc.

Playboy Inc.

Playboy, Inc. operates as a pleasure and leisure company in the United States, Australia, China, the United Kingdom, and ...
View More »

Podcasts